1-3 of 3
Kana Matsumoto
Close
Sort by
Journal Articles

Forodesine Amplifies Host Innate Immune Response through Toll-like Receptor 7 Activation While Preventing Experimental Graft-Versus-Host Disease

Takashi Ikeda, Kazuya Sato, Shinichiro Kawaguchi, Hirofumi Nakano, Junko Izawa, Norihito Takayama, Hiroko Hayakawa, Takashi Nagayama, Kento Umino, Kaoru Morita, Kana Matsumoto, Kentaro Ushijima, Yoshinobu Kanda
Journal: Blood
Blood (2022) 140 (Supplement 1): 12671–12672.
https://doi.org/10.1182/blood-2022-165536
Published: 2022
Journal Articles

Management of Adverse Events Associated with Dasatinib during Early Periods of Therapy in the Treatment of Chronic Myeloid Leukemia -a Clinical Report of Daria-01 Study

Shuichi Mizuta, MD, Hisashi Tsurumi, Masashi Sawa, MD PhD, Kana Matsumoto, PhD, Kotaro Miyao, MD, Takeshi Hara, MD PhD, Takeshi Takahashi, MD PhD, Reona Sakemura, MD, Akio Kohno, MD PhD, Mari Oba, Satoshi Morita, PhD, Junichi Sakamoto, MDPhD, Nobuhiko Emi, MDPhD
Journal: Blood
Blood (2014) 124 (21): 4537.
https://doi.org/10.1182/blood.V124.21.4537.4537
Published: 2014
Journal Articles

Prospective Multicenter Phase II Study of Myeloablative Conditioning Consisted of Intravenous Busulfan and Fludarabine +/− Total Body Irradiation for Older Patients (55 years and older): Results of the JSCT FB09 Study.

Naoyuki Uchida, MD, Michihiro Hidaka, MD, Toru Sakura, MD, Toshihiro Miyamoto, MD, PhD, Tomoaki Fujisaki, MD, PhD, Tetsuya Eto, MD, PhD, Yoshinobu Maeda, MD, PhD, Kenji Fukuno, MD, PhD, Kana Matsumoto, PhD, Kunihiko Morita, PhD, Junji Kishimoto, PhD, Takahiro Fukuda, MD, PhD, Takanori Teshima, MD, PhD, Shuichi Taniguchi, MD, PhD, Shin-Ichiro Mori, MD, Mine Harada, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 3477.
https://doi.org/10.1182/blood.V116.21.3477.3477
Published: 2010